Ferronordic Machines AB (publ) Interim Report January –

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Ferronordic Machines AB (publ) Interim Report January – September 2015

Press Release Stockholm, 24 November 2015 IMPROVED RESULT AND STRONG CASH FLOW THIRD QUARTER 2015 · Revenue decreased by 39% (14% in rubles) to SEK 373m (SEK 616m) · Operating profit increased to SEK 31m (SEK 12m) · Operating margin was 8.3% (1.9%) · EBITDA amounted to SEK 45m (SEK 41m) · The after-tax result amounted to SEK 17m (SEK 0m) · Earnings per ordinary share amounted to SEK 0.47 (SEK -1.20) · Cash flow from operating activities amounted to SEK 183m (SEK -94m) JANUARY - SEPTEMBER 2015 · Revenue decreased by 39% (19% decrease in rubles) to SEK 1,068m (SEK 1,739m) · Operating profit amounted to SEK 43m (SEK 43m) · Operating margin was 4.0% (2.5%) · EBITDA amounted to SEK 97m (SEK 121m) · The after-tax result amounted to SEK 20m (SEK 13m) · Earnings per ordinary share amounted to SEK -1.73 (SEK -2.47) · Cash flow from operating activities amounted to SEK 161m (SEK -145m)  SEK M 2015 2014 2015 2014 Q3 Q3 9M 9M Revenue 372.9 615.6 1 068.4 1 738.9 EBITDA 45.1 41.3 96.7 121.0 Operating profit 31.1 11.9 43.1 43.5 After-tax result 17.2 0.5 20.2 12.8 Net Debt (40.5) 244.7 (40.5) 244.7 Net Debt / EBITDA (0.3х) 1.5х (0.3х) 1.5х COMMENTS BY LARS CORNELIUSSON, CEO AND PRESIDENT: · The market for new machines in Russia continues to be weak. Compared to last year, the number of new units sold is down by about 70%. The falling oil price in combination with the economic sanctions against Russia continue to limit access to capital, resulting in postponed projects and difficulties for customers to finance their investments. In view of this I think we have delivered a strong result during the quarter, especially in terms of cash flow and profitability. We also continue to gain market share. At the end of the quarter, our total market share for the last twelve months was over 10%. · During the quarter we have seen a continued change in product mix, where the lower sales of new machines is compensated by higher sales of parts and used machines. In combination with the cost reductions made, this has led to a significant improvement of our profit margins. We have also reduced our finance costs. In total, this resulted in an after-tax margin of 4% compared to zero in the third quarter last year. · Despite the weak market, we have seen a good cash flow during the year and especially during the third quarter. The operating cash flow during the third quarter amounted to SEK 183m. Thanks to this we managed to end the quarter with a net cash position. · Unfortunately we do not see any signs that the market would recover in the short term and thus expect the rest of 2015 and 2016 to continue to be challenging. However, we remain optimistic about the long term prospects of the Russian construction equipment market. About Ferronordic Machines Ferronordic Machines is the authorized dealer of Volvo Construction Equipment and Terex Trucks in Russia. The company began its operations in June 2010 and has expanded rapidly across Russia and is today well established in all federal districts with almost 70 outlets and approximately 700 employees. In addition to distributing and providing aftermarket support to Volvo Construction Equipment machines, the company has also been appointed aftermarket dealer for Volvo and Renault Trucks as well as dealer for Volvo Penta in certain parts of Russia. The company has also signed up some other high quality brands such as Logset and several attachment manufacturers. The vision of Ferronordic Machines is to be regarded as the leading service- and sales company in the CIS markets. The preference shares of Ferronordic Machines are listed on NASDAQ OMX First North Premier. The company has appointed Avanza Bank AB as its Certified Advisor. http://www.ferronordic.ru For more information, please contact: Anders Blomqvist, CFO and Head of IR, Tel: +46 8 5090 7280 pr@ferronordic.ru Ferronordic Machines discloses the information herein pursuant to the Securities Markets Act and/or the Financial Instruments Act. The information was submitted for publication on 24 November 2015, 1:00pm CET.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 14

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 13

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 14

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 9

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 14

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 15

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 14

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 11

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 8

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Telehealth Trends: A Comprehensive Yearly Insight

Updated Category News Views 346

FAIR Health's Telehealth Tracker: A Milestone Year FAIR Health has reached a significant milestone with its Monthly Telehealth Regional Tracker entering its sixth year. This tracker provides valuable insights into how telehealth usage has evolved, empowering stakeholders to understand trends in healthcare delivery. New Features and Data Insights The latest iteration of...

Continue Reading
Exploring Analog Devices: A $1000 Investment Journey

Updated Category News Views 139

The Growth of Analog Devices Inc (NASDAQ: ADI) Investors have increasingly turned their attention to Analog Devices Inc, a leader in the semiconductor industry. Over the last five years, Analog Devices has consistently outperformed the market, showcasing an annualized return of 16.0%. With a current market capitalization standing at an impressive $119.42 billion, the...

Continue Reading
Celebrating Excellence in Clinical Simulation: Meet the Nominees

Updated Category News Views 110

Highlighting Excellence in Clinical Simulation Awards A Representation of the Best in Simulation Healthcare Education in 2024 Education Management Solutions (EMS), a frontrunner in healthcare simulation and competency management platforms, has proudly announced its nominees for the 16th Annual Excellence in Clinical Simulation Awards. Each year, this noteworthy event...

Continue Reading
Significant Oil Price Drop Benefits Airlines and Cruise Lines

Updated Category News Views 195

Oil Prices Experience a Significant Drop Amid Easing Tensions Oil prices witnessed a noticeable decrease recently, plummeting over 5% during early trading in New York. This shift came as geopolitical tensions in the Middle East appeared to stabilize after an assurance from Israeli Prime Minister Benjamin Netanyahu that Iran’s oil facilities would not be targets in any...

Continue Reading
RxSight, Inc. Faces Legal Challenges: Investors Invited to Join Lawsuit

Updated Category News Views 136

RxSight, Inc. Investors Invited to Participate in Class Action Lawsuit Investors of RxSight, Inc. are becoming aware of significant opportunities to engage in a class action lawsuit. This legal action is being initiated by Bronstein, Gewirtz & Grossman, LLC, a law firm with a national reputation for advocating on behalf of investors. They are notifying shareholders that...

Continue Reading